N
Nancy A. Kernan
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 277
Citations - 17026
Nancy A. Kernan is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 61, co-authored 264 publications receiving 15913 citations. Previous affiliations of Nancy A. Kernan include Cornell University & University of Minnesota.
Papers
More filters
Journal ArticleDOI
Infusions of Donor Leukocytes to Treat Epstein-Barr Virus-Associated Lymphoproliferative Disorders after Allogeneic Bone Marrow Transplantation
Esperanza B. Papadopoulos,Marc Ladanyi,David Emanuel,Stephen Mackinnon,Farid Boulad,Matthew H. Carabasi,Hugo Castro-Malaspina,Barrett H. Childs,Alfred P. Gillio,Trudy N. Small,James W. Young,Nancy A. Kernan,Richard J. O'Reilly +12 more
TL;DR: In a small number of patients, infusions of unirradiated donor leukocytes were an effective treatment for EBV-associated lymphoproliferative disease that arose after allogeneic bone marrow transplantation.
Journal ArticleDOI
Analysis of 462 transplantations from unrelated donors facilitated by the national marrow donor program
Nancy A. Kernan,Glenn E. Bartsch,Robert C. Ash,Patrick G. Beatty,Richard E. Champlin,Alexandra H. Filipovich,James Gajewski,John A. Hansen,Jean P. Henslee-Downey,Jeffrey McCullough,Philip B. McGlave,Herbert A. Perkins,Gordon L. Phillips,Jean E. Sanders,David F. Stroncek,E. Donnall Thomas,Karl G. Blume +16 more
TL;DR: The National Marrow Donor Program has benefited a substantial number of patients in need of marrow transplants from closely HLA-matched unrelated donors and has facilitated the recruitment of unrelated donors into the donor pool and the access to suitable marrow.
Journal ArticleDOI
Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease
Stephen Mackinnon,Esperanza B. Papadopoulos,MH Carabasi,L Reich,Nancy H. Collins,Farid Boulad,Hugo Castro-Malaspina,Barrett H. Childs,Alfred P. Gillio,Nancy A. Kernan +9 more
TL;DR: The dose of donor leukocytes or T cells used may be important in determining both the GVL response and the incidence of GVHD, and 15 of the 17 evaluable patients have become BCR-ABL negative by PCR.
Journal ArticleDOI
Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age
Craig Kollman,Craig W. S. Howe,Claudio Anasetti,Joseph H. Antin,Stella M. Davies,Alexandra H. Filipovich,J Hegland,Naynesh Kamani,Nancy A. Kernan,Roberta King,Voravit Ratanatharathorn,Daniel J. Weisdorf,Dennis L. Confer +12 more
TL;DR: Age should be considered when selecting among comparably HLA-matched volunteer donors and the use of younger donors may lower the incidence of GVHD and improve survival after bone marrow transplantation.
Journal ArticleDOI
Allogeneic sibling umbilical-cord-blood transplantation in children with malignant and non-malignant disease
TL;DR: It is concluded that umbilical cord blood is a sufficient source of transplantable haemopoietic stem cells for children with HLA-identical or Hla-1 antigen disparate sibling donors with very low risk of acute or extensive chronic GVHD.